Adis - Independently Evaluated Drug Information

Adis was established in the 1960's to publish independently evaluated information on new drug compounds.

Of all the publications in medical literature today, Adis journals stand out. Adis journals offer independent, high-quality content with enviable impact factors, but they also offer something else - an unparalleled evaluation of the available evidence on new and established pharmacological interventions.

Adis journals offer the most comprehensive and objective, evidence-based information on:

• Clinical pharmacology
• Drug development
• Pharmacoeconomics
• Drug safety
• Medical biotechnology

Covering all aspects of the drug development continuum from bench-to-bedside, Adis journals are a unique must-have resource for researchers, clinicians, clinical pharmacists and pharmacologists, teachers, students, or anyone with an interest in independent reviews and original research needed to support better therapeutic decisions.

What makes Adis Journals different?

Invited content - drug research and developments in therapy

Adis Editors are very close to new developments and emerging areas of research. Unlike many other journals, Adis content is based around a structured, broad-based program of reviews invited from the most appropriate opinion leaders, which prove to be an invaluable time-saving information resource. The editorial team anticipates topics that will be important across the entire continuum of drug research and developments in therapy, and focuses the reviews to assess both current and future significance of these developments.

Adis drug evaluation programme – Unique feature

Adis Drug Profiles and Drug Evaluations are a unique feature of Adis review journals. Prepared by an experienced team of medical writers, these evidence-based evaluations provide a comprehensive (DE's) or succinct (DP's) review of the pharmacological properties, clinical efficacy and tolerability of the drug, focusing on the clinically important aspects and the drug's place in therapy.

Broad coverage of drug evaluations

Adis Drug Evaluations consider all the available international evidence (including foreign language papers), ensuring the widest possible breadth and depth of coverage.

Thorough drug review process

Adis Drug Evaluations are peer-reviewed by expert international investigators, key opinion leaders, and the clinical research department of the originating manufacturer. Comments from all these sources are very carefully evaluated on the basis of scientific veracity and practical clinical evidence and relevance.

Trusted source - pharmacoevaluation of new and established interventions

Adis writers have an unrivalled reputation and more than 30 years' experience in the pharmacoevaluation of new and established interventions.

Adis Newsletters - latest drug developments

Adis Newsletters report and summarise the latest drug developments published in the international biomedical literature.

Two specialist newsletters, Reactions Weekly and PharmacoEconomics & Outcomes News, provide a time-efficient method for keeping pace with the latest in these niche areas.

Pharmaceutical and biomedical research coverage

Expert news selection by senior specialist editors ensures you get the universe of pharmaceutical and biomedical research delivered in a manageable number of succinct, easy-to-read summaries covering:

• Pharmacovigilance and regulatory news
• International drug safety, pharmacoeconomic and pharmacoepidemiologic research
• Current issues and opinion
• Adverse drug reaction case reports

Our sources

Our expert scientific editors report the latest news from:

• Biomedical publications and their companion supplements
• Scientific meetings
• Media releases
• Regulatory agency websites
• Pharmaceutical company websites

Adis Business Intelligence

Adis Business Intelligence provides a premier set of databases, alert services, and customised solutions developed to help professionals make informed strategic decisions.

Adis R&D Insight

R&D Insight is a searchable drug pipeline database covering all therapeutic  areas and research programs in development worldwide.

Adis Clinical Trials Insight

Clinical Trials Insight is a database enabling the quick identification, tracking, comparison and evaluation of clinical trial evidence.

Adis Journals Marketing
Adis, a Wolters Kluwer business
Chowley Oak Lane
Tattenhall
Cheshire
CH3 9GA, UK

America tel: +1 877 872 2347 (ext 1) or +1 267 757 3421 (ext 1)
UK Tel: +44 207 981 0764
UK Fax: +44(0)1829 770 330
subs@nz.adis.com
clientsupport@wolterskluwer.com (for Adis Client Services)
www.adisonline.com.